Large Outflow of Money Witnessed in Abbott Laboratories

Abbott Laboratories (ABT) : The total money flow in Abbott Laboratories (ABT) was negative ($11.59 million), which signals selling by the traders on Mondays session. They trimmed their holdings by selling the stock on downticks to the tune of $47.07 million. In comparison, the inflow of money into the stock on upticks was $35.48 million. The uptick to downtick ratio was 0.75. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $13.69 million. The value of transactions on uptick was $4.21 million. The negative money flow of ($9.48 million) confirms the selling in Abbott Laboratories (ABT) on strength. The uptick to downtick ratio of block trades was 0.31. Abbott Laboratories (ABT) gained $0.02 at $42.12, a gain of 0.05% over the previous days close. However, the stock registered 0.55% in the week.


Abbott Laboratories has dropped 3.64% during the last 3-month period . Year-to-Date the stock performance stands at -4.53%. Shares of Abbott Laboratories rose by 0.54% in the last five trading days and 12.93% for the last 4 weeks. In a related news, The Securities and Exchange Commission has divulged that Allen Hubert L, Officer (Executive Vice President) of ABBOTT LABORATORIES, had unloaded 3,400 shares at an average price of $37.14 in a transaction dated on June 28, 2016. The total value of the transaction was worth $126,276.

Abbott Laboratories (NYSE:ABT): On Mondays trading session , Opening price of the stock was $42.05 with an intraday high of $42.229. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $41.81. However, the stock managed to close at $42.09, a loss of 0.02% for the day. On the previous day, the stock had closed at $42.1. The total traded volume of the day was 7,524,201 shares.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.